Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Campbell, Lucy J ^a   Dew, Tracy ^b   Salota, Rashim ^b   Cheserem, Emily ^b   Hamzah, Lisa ^a,b   Ibrahim, Fowzia ^a   Sarafidis, Pantelis A ^a   Moniz, Caje F ^b   Hendry, Bruce M ^a   Poulton, Mary ^b   Sherwood, Roy A ^b   Post, Frank A ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Albuminuria; Cystatin C; HIV; Neutrophil gelatinase associated lipocalin; NGAL; Proteinuria; RBP; Retinol binding protein; Tenofovir

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; RETINOID BINDING PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PROTEIN URINE LEVEL;

ACUTE-PHASE PROTEINS; ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; HIV INFECTIONS; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; PROTEINS; PROTEINURIA; PROTO-ONCOGENE PROTEINS; RENAL INSUFFICIENCY, CHRONIC; RETINOL-BINDING PROTEINS, CELLULAR; SERUM ALBUMIN; YOUNG ADULT;

EID: 84864817945     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-85     Document Type: Article

References (47)

1. Recent developments in HIV and the kidney. Post FA, Holt SG, Curr Opin Infect Dis 2009 22 1 43 48 10.1097/QCO.0b013e328320ffec 19106702
2. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD, AIDS 2004 18 3 541 546 10.1097/00002030-200402200-00022 15090808
3. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, et al. Kidney Int 2004 66 3 1145 1152 10.1111/j.1523-1755.2004.00865.x 15327410
4. Predictors of renal outcome in HIV-associated nephropathy. Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, Johnson L, Fisher M, Holt SG, Bhagani S, et al. Clin Infect Dis 2008 46 8 1282 1289 10.1086/529385 18444868
5. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG, AIDS 2009 23 16 2143 2149 10.1097/QAD.0b013e3283313c91 19684507
6. CD4+ count-guided interruption of antiretroviral treatment. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, et al. N Engl J Med 2006 355 22 2283 2296 17135583
7. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, Kambugu A, Gilks CF, Mugyenyi P, Munderi P, et al. Clin Infect Dis 2008 46 8 1271 1281 10.1086/533468 18444867
8. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, Smurzynski M, Albert JM, AIDS 2008 22 4 481 487 10.1097/QAD.0b013e3282f4706d 18301060
9. HIV viremia and changes in kidney function. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG, AIDS 2009 23 9 1089 1096 10.1097/QAD.0b013e32832a3f24 19352136
10. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. Ibrahim F, Naftalin C, Cheserem E, Roe J, Campbell LJ, Bansi L, Hendry BM, Sabin C, Post FA, AIDS 2010 24 14 2239 2244 10.1097/QAD.0b013e32833c85d6 20634665
11. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, Fine DM, Nephrol Dial Transplant 2006 21 10 2809 2813 10.1093/ndt/gfl337 16864598
12. Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, Edwards S, Connolly J, Holt SG, Hendry BM, et al. AIDS 2009 23 18 2517 2521 10.1097/QAD. 0b013e3283320e12 19752713
13. Chronic renal failure among HIV-1-infected patients. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD, AIDS 2007 21 9 1119 1127 10.1097/QAD.0b013e3280f774ee 17502722
14. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD, AIDS 2010 24 11 1667 1678 10.1097/QAD.0b013e328339fe53 20523203
15. Spectrum of chronic kidney disease in HIV-infected patients. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA, HIV Med 2009 10 6 329 336 10.1111/j.1468-1293.2008.00691.x 19226409
16. Prevention and management of non-infectious co-morbidities in HIV, http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ eacsguidelines-6.pdf
17. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, et al. Clin Infect Dis 2005 40 11 1559 1585 10.1086/430257 15889353
18. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P, Mackie N, Muir D, et al. HIV Med 2012 13 1 1 44 10.1111/j.1468-1293.2011.00971.x 22830364
19. The nephrologist in the HAART era. Izzedine H, Deray G, AIDS 2007 21 4 409 421 10.1097/QAD.0b013e328011ec40 17301559
20. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G, Clin Infect Dis 2006 42 2 283 290 10.1086/499048 16355343
21. Tenofovir-associated renal and bone toxicity. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO, HIV Med 2009 10 8 482 487 10.1111/j.1468-1293.2009.00716.x 19459988
22. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Ceron D, J Acquir Immune Defic Syndr 2004 35 3 269 273 10.1097/00126334-200403010-00007 15076241
23. Renal safety of tenofovir in HIV treatment-experienced patients. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, Launay-Vacher V, Deray G, AIDS 2004 18 7 1074 1076 10.1097/00002030-200404300-00019 15096814
24. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, Rivas P, Albalater M, Blanco F, Moreno V, et al. AIDS 2009 23 6 689 696 10.1097/QAD. 0b013e3283262a64 19262355
25. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O'Farrell S, Unwin RJ, Williams IG, Am J Kidney Dis 2009 54 6 1034 1042 10.1053/j.ajkd.2009.07.012 19783343
26. 16th Conference on Retroviruses and Opportunistic Infections. Fux C, Opravil M, Cavassini M, Calmy A, Flepp M, Gurtner-Delafuente V, Stoeckle M, Schmid P, Rauch A, Furrer H, et al. Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study Montreal, Canada 2009
27. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, Gonzalez-Pardo G, Khoo S, Back D, et al. Clin Infect Dis 2009 48 11 108 116 10.1086/598507 19400747
28. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. Rodriguez-Novoa S, Labarga P, D'Avolio A, Barreiro P, Albalate M, Vispo E, Solera C, Siccardi M, Bonora S, Di Perri G, et al. AIDS 2010 24 7 1064 1066 10.1097/QAD. 0b013e32833202e2 20299966
29. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K, Nephrol Dial Transplant 2011 26 10 3224 3229 10.1093/ndt/gfr020 21372250
30. Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, et al. J Acquir Immune Defic Syndr 2010 55 1 49 57 10.1097/QAI.0b013e3181dd911e 20431394
31. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C, Klein D, J Acquir Immune Defic Syndr 2010 53 1 62 69 10.1097/QAI.0b013e3181be6be2 19838127
32. Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Bonora S, Di Perri G, Back DJ, et al. J Infect Dis 2011 204 1 145 153 10.1093/infdis/jir215 21628669
33. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. Jaafar A, Seronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I, AIDS 2009 23 2 257 259 10.1097/QAD.0b013e328314e382 19098496
34. Biomarkers of impaired renal function. Post FA, Wyatt CM, Mocroft A, Curr Opin HIV AIDS 2010 5 6 524 530 10.1097/COH.0b013e32833f203e 20978396
35. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, et al. Lancet 2005 365 9466 1231 1238 10.1016/S0140-6736(05)74811-X 15811456
36. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. J Hypertens 2007 25 6 1105 1187 10.1097/HJH.0b013e3281fc975a 17563527
37. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Sola-Del Valle DA, Mohan S, Cheng JT, Paragas NA, Sise ME, D'Agati VD, Barasch J, Nephrol Dial Transplant 2011 26 7 2387 2390 10.1093/ndt/gfr258 21555394
38. Urinary NGAL marks cystic disease in HIV-associated nephropathy. Paragas N, Nickolas TL, Wyatt C, Forster CS, Sise M, Morgello S, Jagla B, Buchen C, Stella P, Sanna-Cherchi S, et al. J Am Soc Nephrol 2009 20 8 1687 1692 10.1681/ASN.2009010065 19628667
39. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Han TM, Naicker S, Ramdial PK, Assounga AG, Kidney Int 2006 69 12 2243 2250 10.1038/sj.ki.5000339 16672914
40. Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray AG, J Infect Dis 2006 194 11 1481 1491 10.1086/508546 17083032
41. Analysis of molecular forms of urine Retinol-Binding Protein in Fanconi Syndrome and design of an accurate immunoassay. Burling KA, Cutillas PR, Church D, Lapsley M, Norden AG, Clin Chim Acta 2012 413 3-4 483 489 22120727
42. Microalbuminuria in HIV infection. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, Wohl D, Shlipak MG, AIDS 2007 21 8 1003 1009 10.1097/QAD.0b013e3280d3587f 17457094
43. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Sarafidis PA, Bakris GL, Nephrol Dial Transplant 2006 21 9 2366 2374 10.1093/ndt/gfl309 16782993
44. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CC, Rompalo AM, Schuman P, Klein RS, J Acquir Immune Defic Syndr 2003 32 2 203 209 10.1097/00126334-200302010-00013 12571531
45. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG, Circulation 2010 121 5 651 658 10.1161/CIRCULATIONAHA.109.898585 20100969
46. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG, AIDS 2010 24 3 387 394 10.1097/QAD.0b013e3283359253 20019575
47. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. Wyatt CM, Hoover DR, Shi Q, Seaberg E, Wei C, Tien PC, Karim R, Lazar J, Young MA, Cohen MH, J Acquir Immune Defic Syndr 2010 55 1 73 77 10.1097/QAI.0b013e3181cc1070 20098331